The Medicines for Children Research Network (MCRN) is funded by the National Institute for Health Research (NIHR) set up in 2005 to improve the coordination, speed and quality of randomised controlled trials and other well designed studies for children and adolescents, including those for prevention, diagnosis and treatment.
It is currently recruiting parents or carers to join Clinical Studies Groups (CSGs) responsible for addressing research priorities, and helping to ensure that studies on medicines for children are developed and carried out to best meet the needs and wishes of children and families.
There are current vacancies for the following MCRN CSGs:
-MCRN/Arthritis Research UK Paediatric Rheumatology Clinical Studies Group
The Rheumatology Clinical Studies group is a partnership between Arthritis Research UK and the Medicines for Children Research Network
We are particularly interested to receive applications from parents or carers who fulfil the following criteria:
-Experience of looking after a child with a rheumatological condition
-Excellent communication skills
-Experience of working in groups/committees
The time to participate in approximately 2 face to face meetings a year and monthly teleconferences
Parent/carer members of CSGs are offered full support as well as an attendance fee and expenses for agreed meetings and training. All appointments are for 3 years in the first instance.
Interested applicants are encouraged to contact Jenny Newman, MCRN Consumer Liaison Manager at: Jennifer.email@example.com or +44 (0) 151 282 4534 and notify Ailsa Bosworth at NRAS firstname.lastname@example.org upon applying. Application packs are available upon request. Alternatively please contact the MCRN Coordinating Centre on + 44 (0) 151 252 5067. Deadline for return of applications is 25th April 2013. Interviews will be held via teleconference shortly afterwards.
The NIHR Medicines for Children Research Network is part of the NIHR Clinical Research Network, which supports research to make patients, and the NHS, better.